Asalyxa Bio
Pioneering a breakthrough in therapeutics by targeting over-reactive immune cells to address significant unmet medical needs across various disease conditions.
Pioneering a breakthrough in therapeutics by targeting over-reactive immune cells to address significant unmet medical needs across various disease conditions.
Asalyxa Bio, a **biotechnology** startup founded in **2020**, is focused on pioneering a breakthrough in therapeutics by targeting over-reactive immune cells to address significant unmet medical needs across various disease conditions. The company's **slogan** encapsulates its mission to innovate and address critical medical conditions resulting from improper immune signaling. Asalyxa Bio's platform technology enables the targeted delivery of both existing and new medicines directly into hyperactive immune cells, offering potential use across a broad spectrum of diseases and conditions. In its latest milestone, Asalyxa Bio secured a **Seed Round investment** on **26 July 2021** from **Michigan Rise**. This investment reflects confidence in the company's innovative approach to addressing unmet medical needs through its platform technology. Asalyxa Bio's dedication to creating novel treatments for critical medical conditions has attracted support from notable investors, positioning the company for further development and potential breakthroughs in the field of therapeutics.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Seed Round | Unknown | 1 |
|
26 Jul 2021 |
| Seed Round | $2.00M | 6 |
-logo.png){kind=logo}
|
23 Feb 2021 |
No recent news or press coverage available for Asalyxa Bio.
We care about your data, and we'd love to use cookies make your experience better.
